TaiMed Biologics
Latest round
- Series B
Last raised
- Mar 2010
Total raised
- $22M
Investors
- 1
About TaiMed Biologics
Established in 2007 and based in Taipei, China, TaiMed Biologics Inc. operates as a biologics developer that focuses on the clinical development of biotherapeutics. It has an approximately 60,000 square feet of facility. The company is headquartered in Taipei, and has a branch in Hsinchu and a subsidiary in the USA. In March 2018, its product TMB-355 was approved by the US FDA as a new protein drug. Dayi He, the co-founder of the company, is an academician of Academia Sinica and director and CEO of the AIDS Research Center. The company cooperates with tanvex, WuXi AppTec and Samsung Biologics, etc. The company is engages in the research and development of biotherapeutics. Its products include Trogarzo® intravenous injection, Trogarzo® intravenous bolus injection, Trogarzo® intramuscular injection, TMB-365 and TMB-380 double antibody compound combination. The company also provides biological agents commissioned development and manufacturing (CDMO) services.
Who invested in TaiMed Biologics
1 investor across 1 round
See all investors in TaiMed Biologics
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Series B
Mar 1, 2010
Amount
$22M
Investors
Questions about TaiMed Biologics
Who invested in TaiMed Biologics?
TaiMed Biologics has 1 investor on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has TaiMed Biologics raised?
TaiMed Biologics has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did TaiMed Biologics last raise money?
TaiMed Biologics's most recent round on record is a Series B, in Mar 2010.
What does TaiMed Biologics do?
Established in 2007 and based in Taipei, China, TaiMed Biologics Inc.
Where is TaiMed Biologics headquartered?
TaiMed Biologics is headquartered in Taipei, Taiwan - China.
Which VCs invest in companies like TaiMed Biologics?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at TaiMed Biologics's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series B
Raising like TaiMed Biologics? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.